Ocugen (OCGN) Q3 2024 Earnings Call Transcript [Yahoo! Finance]
Ocugen, Inc. (OCGN)
Company Research
Source: Yahoo! Finance
Call Participants Operator Good morning and welcome to Ocugen's third quarter 2024 financial results and business update. [Operator instructions] I will now turn the call over to Tiffany Hamilton, Ocugen's, head of corporate communications. You may begin. Tiffany Hamilton Head of Corporate Communications Thank you, operator and good morning, everyone. Joining me on today's call and webcast is Dr. Shankar Musunuri, Ocugen's, chairman, CEO and co-founder, who will provide a business update and an overview of our clinical and operational progress. Ramesh Ramachandran, our chief accounting officer, who is transitioning from Mike Breininger, interim chief accounting officer is also on the call to provide a financial update for the quarter ended September 30th, 2024. Dr. Huma Qamar, chief medical officer; and Dr. Arun Upadhyay, chief scientific officer, will be available to answer questions following the presentation. This morning, we issued a press release detailing associated b
Show less
Read more
Impact Snapshot
Event Time:
OCGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCGN alerts
High impacting Ocugen, Inc. news events
Weekly update
A roundup of the hottest topics
OCGN
News
- Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration [Yahoo! Finance]Yahoo! Finance
- Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular DegenerationGlobeNewswire
- Ocugen CEO to Present at Oppenheimer Movers in Rare Disease SummitGlobeNewswire
- Ocugen CEO to Present at NobleCon20 – Noble Capital Markets' 20th Annual Emerging Growth Equity Conference [Yahoo! Finance]Yahoo! Finance
- Ocugen CEO to Present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity ConferenceGlobeNewswire
OCGN
Earnings
- 8/8/24 - Beat
OCGN
Sec Filings
- 12/3/24 - Form 8-K
- 12/2/24 - Form 4
- 11/26/24 - Form 4
- OCGN's page on the SEC website